Stakeholder Opposes Proposed Astex $886 Million Sale To Otsuka
This article was originally published in PharmAsia News
Executive Summary
The proposed Otsuka Holdings purchase of Astez Pharmaceuticals for $886 million has been jeopardized by the opposition of the U.S.-based company's largest shareholder, the Sarissa Capital hedge fund.